Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Section 4 of 6

Clinical evidence

188 evidence topics · 24 sources

Study summaries

AURORA

Objective
Location and study date
Registry site count and site locations by country
CountrySite locations listed in the registry
United States“Tucson, Arizona, United States, 85718”; “Carlsbad, California, United States, 92011”; “Los Angeles, California, United States, 90095”; “Orange, California, United States, 92868”; “Aurora, Colorado, United States, 80045”; “Washington D.C., District of Columbia, United States, 20007”; “Maitland, Florida, United States, 32751”; “Tampa, Florida, United States, 33612”; “O'Fallon, Illinois, United States, 62269”; “Fairway, Kansas, United States, 66205”; “Lexington, Kentucky, United States, 40536”; “Boston, Massachusetts, United States, 02111”; “Amherst, New York, United States, 14226”; “New York, New York, United States, 10027”; “New York, New York, United States, 10065”; “Chapel Hill, North Carolina, United States, 27599”; “Charlotte, North Carolina, United States, 28204”; “Portland, Oregon, United States, 97239”; “Philadelphia, Pennsylvania, United States, 19104”; “Pittsburgh, Pennsylvania, United States, 15213”; “Houston, Texas, United States, 77030”; “Seattle, Washington, United States, 98195”; “Milwaukee, Wisconsin, United States, 53215”
Canada“Toronto, Canada”
Italy“Rome, Italy”
Poland“Krakow, Poland”
Serbia“Belgrade, Serbia”
Spain“Barcelona, Spain”; “Madrid, Spain”
Turkey“Ankara, Turkey (Türkiye)”; “Istanbul, Turkey (Türkiye)”
United Kingdom“Birmingham, United Kingdom”; “Sheffield, United Kingdom”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using MG-ADL response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AURORA has reported no efficacy or safety results. The registry record (last update posted 2026-09-01) lists the study as active and not recruiting, with estimated primary completion on 2026-12-30 and estimated study completion on 2027-09-30; record version 16 had listed estimated primary completion on 2026-11-30. The company expects a data readout in the first quarter of 2027.
  • Enrollment differs by source: the company states approximately 100 participants, registry record version 16 listed an estimated enrollment of 100, and the current registry record lists an actual enrollment of 128.
  • The primary endpoint is the proportion of participants with an MG-ADL improvement of 3 points or more at month 4 compared with placebo. The registry lists a crossover assignment model, a double-blind Part 1 of about 6 months, and an open-label Part 2 of about 8 months for eligible participants, and the company trial schema shows optional Descartes-08 infusions with follow-up at months 5, 6, 9, and 12.
  • The phase 2b report stated plans to use the MGC score as the primary outcome in a subsequent phase 3 trial; in AURORA, MGC improvement of 4 points or more at month 4 is a secondary endpoint. One publication reports that the MG-ADL score was considered “a bar too low” for approval of a therapy given the 2-point threshold for clinically meaningful improvement. Another reports that a 3-point MG-ADL change had a specificity of 90% and a sensitivity of 62%, that no publicly available FDA guidance on an MG-ADL responder threshold exists, and that the eculizumab label refers to REGAIN results using a 3-point improvement.
  • Eligibility is limited to adults with an anti-AChR antibody titer or anti-AChR cluster antibody above the reference upper normal limit, MGFA class 2 to 4, and an MG-ADL total score of 6 or more. Participants diagnosed within 12 months of screening, those with no history of systemic gMG treatment other than acetylcholinesterase inhibitors, those treated with rituximab or ocrelizumab within 12 months, and those with prior BCMA-directed therapy are excluded. In the phase 2b mITT population, 6 participants (23.1%) were triple seronegative and 1 (3.8%) was LRP4 autoantibody-positive.
  • The company's Form 10-K states that a trial conducted under a Special Protocol Assessment agreement that meets its endpoints carries no guarantee that the FDA will accept or approve a marketing application.

MG-001 phase 2b

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using MGC response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline demographics and disease characteristics, mITT population
CharacteristicDescartes-08 (n = 15)Placebo (n = 11)Total (n = 26)
Mean age, years (s.d.)“56.7 (16.39)”View highlighted excerpt for this quote“59.0 (13.96)”View highlighted excerpt for this quote“57.7 (15.16)”View highlighted excerpt for this quote
Female, n (%)“10 (66.7)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“16 (61.5)”View highlighted excerpt for this quote
Mean weight, kg (s.d.)“93.83 (20.001)”View highlighted excerpt for this quote“105.37 (27.496)”View highlighted excerpt for this quote“98.71 (23.669)”View highlighted excerpt for this quote
White, non-Hispanic, n (%)“13 (86.7)”View highlighted excerpt for this quote“11 (100.0)”View highlighted excerpt for this quote“24 (92.3)”View highlighted excerpt for this quote
MGFA class IIa at screening, n (%)“0”View highlighted excerpt for this quote“2 (18.2)”View highlighted excerpt for this quote“2 (7.7)”View highlighted excerpt for this quote
MGFA class IIb at screening, n (%)“4 (26.7)”View highlighted excerpt for this quote“1 (9.1)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
MGFA class IIIa at screening, n (%)“2 (13.3)”View highlighted excerpt for this quote“5 (45.5)”View highlighted excerpt for this quote“7 (26.9)”View highlighted excerpt for this quote
MGFA class IIIb at screening, n (%)“8 (53.3)”View highlighted excerpt for this quote“3 (27.3)”View highlighted excerpt for this quote“11 (42.3)”View highlighted excerpt for this quote
MGFA class IVa at screening, n (%)“1 (6.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.8)”View highlighted excerpt for this quote
Median age at disease onset, years (range)“55 (16–76)”View highlighted excerpt for this quote“51 (25–71)”View highlighted excerpt for this quote“53 (16–76)”View highlighted excerpt for this quote
Median duration of disease, years (range)“5.5 (2–23)”View highlighted excerpt for this quote“10 (4–26)”View highlighted excerpt for this quote“6 (2–26)”View highlighted excerpt for this quote
Anti-AChR antibody, n (%)“11 (73.3)”View highlighted excerpt for this quote“8 (72.7)”View highlighted excerpt for this quote“19 (73.1)”View highlighted excerpt for this quote
Anti-LRP4 antibody, n (%)“1 (6.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.8)”View highlighted excerpt for this quote
Triple seronegative, n (%)“3 (20.0)”View highlighted excerpt for this quote“3 (27.3)”View highlighted excerpt for this quote“6 (23.1)”View highlighted excerpt for this quote
Mean QMG score (s.d.)“17.3 (7.31)”View highlighted excerpt for this quote“14.7 (4.03)”View highlighted excerpt for this quote“16.2 (6.17)”View highlighted excerpt for this quote
Mean MG-ADL score (s.d.)“10.5 (3.20)”View highlighted excerpt for this quote“9.8 (2.79)”View highlighted excerpt for this quote“10.2 (3.00)”View highlighted excerpt for this quote
Mean MGC score (s.d.)“16.4 (6.39)”View highlighted excerpt for this quote“15.7 (3.95)”View highlighted excerpt for this quote“16.1 (5.41)”View highlighted excerpt for this quote
Mean MG-QoL-15r score (s.d.)“19.1 (7.62)”View highlighted excerpt for this quote“17.7 (4.73)”View highlighted excerpt for this quote“18.5 (6.48)”View highlighted excerpt for this quote
Diagnosis of thymoma, n (%)“1 (6.7)”View highlighted excerpt for this quote“4 (36.4)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
Previous thymectomy, n (%)“4 (26.7)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“10 (38.5)”View highlighted excerpt for this quote
Previous MG crisis requiring intubation, n (%)“2 (13.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.7)”View highlighted excerpt for this quote
Previous and ongoing MG therapies, mITT population
TherapyDescartes-08 (n = 15)Placebo (n = 11)Total (n = 26)
Previous pyridostigmine, n (%)“9 (60.0)”View highlighted excerpt for this quote“9 (81.8)”View highlighted excerpt for this quote“18 (69.2)”View highlighted excerpt for this quote
Previous prednisone, n (%)“7 (46.7)”View highlighted excerpt for this quote“5 (45.5)”View highlighted excerpt for this quote“12 (46.2)”View highlighted excerpt for this quote
Previous other immunosuppressants, n (%)“7 (46.7)”View highlighted excerpt for this quote“9 (81.8)”View highlighted excerpt for this quote“16 (61.5)”View highlighted excerpt for this quote
Previous complement inhibitor, n (%)“3 (20.0)”View highlighted excerpt for this quote“5 (45.5)”View highlighted excerpt for this quote“8 (30.8)”View highlighted excerpt for this quote
Previous FcRn inhibitor, n (%)“5 (33.3)”View highlighted excerpt for this quote“4 (36.4)”View highlighted excerpt for this quote“9 (34.6)”View highlighted excerpt for this quote
Previous intravenous immunoglobulin, n (%)“11 (73.3)”View highlighted excerpt for this quote“9 (81.8)”View highlighted excerpt for this quote“20 (76.9)”View highlighted excerpt for this quote
Previous plasma exchange, n (%)“3 (20.0)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“9 (34.6)”View highlighted excerpt for this quote
Ongoing pyridostigmine, n (%)“11 (73.3)”View highlighted excerpt for this quote“7 (63.6)”View highlighted excerpt for this quote“18 (69.2)”View highlighted excerpt for this quote
Ongoing prednisone, n (%)“9 (60.0)”View highlighted excerpt for this quote“4 (36.4)”View highlighted excerpt for this quote“13 (50.0)”View highlighted excerpt for this quote
Ongoing azathioprine, n (%)“3 (20.0)”View highlighted excerpt for this quote“2 (18.2)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
Ongoing mycophenolate mofetil, n (%)“3 (20.0)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“9 (34.6)”View highlighted excerpt for this quote
Ongoing complement inhibitor, n (%)“4 (26.7)”View highlighted excerpt for this quote“1 (9.1)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
Number of concomitant MG therapies, median (range)“2 (1–4)”View highlighted excerpt for this quote“2 (1–5)”View highlighted excerpt for this quote“2 (1–5)”View highlighted excerpt for this quote
Baseline characteristics of all randomized participants (safety population)
CharacteristicPlacebo (n=16)Descartes-08 (n=20)
Female, % (n)“62.5 (10)”“55.0 (11)”
Age, years, mean (SD)“57.8 (14.4)”“59.4 (14.7)”
Median duration of disease, years (range)“5 (1–23)”“6 (0–26)”
MGFA class III at screening, % (n)“68.8 (11)”“70.0 (14)”
AChR+, % (n)“75.0 (12)”“80.0 (16)”
Sero-negative, % (n)“25.0 (4)”“15.0 (3)”
Diagnosis of thymoma, % (n)“31.3 (5)”“10.0 (2)”
Previous thymectomy, % (n)“50.0 (8)”“30.0 (6)”
Previous FcRn antagonist, % (n)“37.5 (6)”“30.0 (6)”
Previous complement inhibitor, % (n)“37.5 (6)”“15.0 (3)”
Efficacy results
Primary endpoint and month 3 score changes, mITT population (Descartes-08 n = 15; placebo n = 11)
Outcome at month 3Descartes-08 (n = 15)Placebo (n = 11)
MGC score, baseline, mean (s.d.)“16.4 (6.39)”View highlighted excerpt for this quote“15.7 (3.95)”View highlighted excerpt for this quote
MGC score, month 3, mean (s.d.)“11.4 (8.57)”View highlighted excerpt for this quote“13.5 (8.48)”View highlighted excerpt for this quote
MGC change from baseline at month 3, mean (s.d.)“−5.0 (6.67)”View highlighted excerpt for this quote“−2.3 (7.73)”View highlighted excerpt for this quote
MGC responder (≥5-point reduction), n (%)“10 (66.7)”View highlighted excerpt for this quote“3 (27.3)”View highlighted excerpt for this quote
MG-ADL score, baseline, mean (s.d.)“10.5 (3.20)”View highlighted excerpt for this quote“9.8 (2.79)”View highlighted excerpt for this quote
MG-ADL score, month 3, mean (s.d.)“6.4 (4.31)”View highlighted excerpt for this quote“8.2 (3.82)”View highlighted excerpt for this quote
MG-ADL change from baseline at month 3, mean (s.d.)“−4.1 (3.38)”View highlighted excerpt for this quote“−1.6 (4.06)”View highlighted excerpt for this quote
QMG score, baseline, mean (s.d.)“17.3 (7.3)”View highlighted excerpt for this quote“14.7 (4.03)”View highlighted excerpt for this quote
QMG score, month 3, mean (s.d.)“13.4 (7.53)”View highlighted excerpt for this quote“13.2 (5.12)”View highlighted excerpt for this quote
QMG change from baseline at month 3, mean (s.d.)“−3.9 (4.37)”View highlighted excerpt for this quote“−1.5 (4.27)”View highlighted excerpt for this quote
MG-ADL and QMG changes through month 12, Descartes-08 group, mITT population (open-label follow-up)
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events, day 1 to month 3, safety population
Event, n (%)Descartes-08 (n = 20)Placebo (n = 16)
Any AE“17 (85.0)”View highlighted excerpt for this quote“13 (81.3)”View highlighted excerpt for this quote
SAE“5 (25.0)”View highlighted excerpt for this quote“3 (18.8)”View highlighted excerpt for this quote
Any AE leading to discontinuation of study drug“1 (5.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Any infection“8 (40.0)”View highlighted excerpt for this quote“6 (37.5)”View highlighted excerpt for this quote
Upper respiratory infection“3 (15.0)”View highlighted excerpt for this quote“4 (25.0)”View highlighted excerpt for this quote
HSV reactivation“3 (15.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
COVID-19 infection“1 (5.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Catheter-related infection“1 (5.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Urinary tract infection“0”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Any IRR“16 (80.0)”View highlighted excerpt for this quote“9 (56.3)”View highlighted excerpt for this quote
Headache“10 (50.0)”View highlighted excerpt for this quote“7 (43.8)”View highlighted excerpt for this quote
Nausea“9 (45.0)”View highlighted excerpt for this quote“4 (25.0)”View highlighted excerpt for this quote
Fever“11 (55.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Chills“12 (60.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Myalgia“7 (35.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Fatigue“7 (35.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Limb swelling“2 (10.0)”View highlighted excerpt for this quote“2 (12.5)”View highlighted excerpt for this quote
Diarrhea“3 (15.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Overall adverse events and grade 3 events, safety population

“Adverse event (AE) rates were similar between groups, with 17 of 20 (85.0%) participants in the Descartes-08 group and 13 of 16 (81.3%) participants in the placebo group reporting at least one AE during the study (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most AEs were mild or moderate (Common Terminology Criteria for AEs (CTCAE) grades 1–2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among 20 participants in the safety population randomized to Descartes-08 and 16 participants randomized to placebo, 5 (25.0%) and 2 (12.5%), respectively, experienced a grade 3 AE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the Descartes-08 group, grade 3 AEs included a vasovagal reaction, a bacterial infection, fever, a herpes simplex virus (HSV) reactivation and a thromboembolic event (thrombosis of a central venous port placed several years before enrollment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Meanwhile, grade 3 AEs reported in the placebo group included disease exacerbation and urinary tract infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of these, only the case of fever was deemed possibly treatment-related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Serious adverse events and absence of grade 4 or 5 events, safety population
Treatment-emergent adverse events, AChR antibody-positive participants
Event, n (%)Descartes-08 (n=16)Placebo (n=12)
Any AE“16 (100)”“12 (100)”
Serious AE“4 (25.0)”“2 (16.7)”
Any AE leading to discontinuation of study drug“1 (6.3)”“1 (8.3)”
Any infusion-related reaction“13 (81.3)”“7 (58.3)”
Fever“8 (50.0)”“1 (8.3)”
Chills“10 (62.5)”“0”
Any infection“6 (37.5)”“5 (41.7)”
Herpes simplex reactivation“2 (12.5)”“0”
Study limitations
Summary
  • Sample size and power: the authors describe a phase 2 study with a limited sample size and 80% power to detect differences in the primary outcome, which makes comparisons of secondary outcomes descriptive. The power calculation assumed 15 participants per group, 87% responders with Descartes-08, and 40% with placebo. Numerical differences in secondary scores did not meet the hierarchical threshold for formal testing, and placebo responses during early follow-up led to a lack of statistical significance in the secondary efficacy outcomes.
  • Analysis sets: of 45 participants who underwent leukapheresis, 9 (20.0%) were not randomized because fewer than six doses were manufactured. Of 36 randomized participants (safety population), the primary efficacy analysis included the 26 enrolled at an academic medical center with at least one postinfusion follow-up. The protocol specified sensitivity analyses in the overall ITT and per-protocol populations. The company's 2024 topline release reported the mITT population as 14 Descartes-08 and 12 placebo participants and the safety population as 19 and 17, where the published report gives 15 and 11, and 20 and 16.
  • Change of primary endpoint: on January 8, 2024, after 44 participants had enrolled and before unblinding and database lock, the primary outcome was changed from the MG-ADL score to the MGC score, and the 5-point MGC threshold, chosen to account for higher-than-expected baseline MGC scores, exceeds the 3-point change considered clinically meaningful. The primary efficacy population was defined in protocol amendment v4.2 (June 19, 2024).
  • Allocation and baseline imbalance: randomization had no stratification by site, and the authors state that this, the small sample, and the rate of participants not randomized likely led to unequal allocation. Disease duration and the rate of thymoma were higher in the placebo group, and triple seronegative participants (23.1%) were overrepresented compared with the general population, which the authors state affected the magnitude of the early placebo response. A transient effect of leukapheresis cannot be excluded.
  • Subgroups: subgroup analyses compared participants by AChR antibody status, early- or late-onset disease (a prespecified analysis), prior exposure to complement and FcRn inhibitors, and development of fever, and an analysis of cell dose and MGC response was post hoc. The authors state that the small sample and heterogeneous population severely limit inferences about subgroups, and that the difference between biologic-naive and biologic-exposed participants may represent a true difference in biology, an artifact of a small sample size, or more treatment-refractory disease.
  • Follow-up beyond month 3: all 11 placebo participants received open-label Descartes-08 after month 3, and month 4 to month 12 results are reported for the Descartes-08 group. As of a March 31, 2025 cutoff, the company reported that 12 of 15 Descartes-08 participants in the primary efficacy dataset completed month 12 and that 3 were lost to follow-up after month 3, 2 of whom were MGC responders at month 3.
  • Other author-stated limitations: radioimmunoassay antibody testing may be insufficiently sensitive to changes in antibody subtype, mode of activity, and epitope; the protocol held prednisone stable until month 6 and allowed no change in nonsteroidal immunosuppressants; and fevers, chills, and myalgias were more common with Descartes-08 and may have affected the assessment of severity scales.
  • Figures that differ between sources or within the report: sustained clinically meaningful response at month 12 is 83.0% in the abstract and 80.0% in the Discussion; minimum symptom expression is 33.0% in the abstract and 33.3% (4/12) in the Results; minimum symptom expression among biologic-naive participants is 55.60% in the abstract and 55.6% (5/9) in the Results, and the company's April 2025 release gives 57% (4/7) for biologic-naive participants with follow-up beyond month 3. The value −4.8 is reported both for the month-12 MG-ADL change and for the month-4 QMG change. The placebo MG-ADL change at month 3 in the AChR antibody-positive subgroup is 0.6 in the paper and −0.6 in a 2026 company slide presentation. The text reports prior or ongoing complement inhibitor use in the Descartes-08 group as “n = 7/15, 40.0%”.

MG-001 phase 1b/2a

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Care setting, post-infusion monitoring, premedication, and no lymphodepletion
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline characteristics by part and arm: all 14 participants
CharacteristicPart 1 (n=3)Part 2 Arm 1, twice weekly (n=3)Part 2 Arm 2, weekly (n=7)Part 2 Arm 3, monthly (n=1)All participants (n=14)
Age, mean (SD), years“57 (16)”View highlighted excerpt for this quote“43 (26)”View highlighted excerpt for this quote“52 (16·8)”View highlighted excerpt for this quote“70”View highlighted excerpt for this quote“52 (18)”View highlighted excerpt for this quote
Female sex, no. (%)“2/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“5/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“10 (71%)”View highlighted excerpt for this quote
MGFA class II at screening“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (21%)”View highlighted excerpt for this quote
MGFA class III at screening“3/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“4/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“10 (72%)”View highlighted excerpt for this quote
MGFA class IV at screening“0”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (7%)”View highlighted excerpt for this quote
Duration of disease, median (range), years“13 (5–25)”View highlighted excerpt for this quote“14 (4–15)”View highlighted excerpt for this quote“16 (3–27)”View highlighted excerpt for this quote“26”View highlighted excerpt for this quote“14 (3–27)”View highlighted excerpt for this quote
Anti-AChR antibody“3/3”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“4/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“11 (79%)”View highlighted excerpt for this quote
Anti-MuSK antibody“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (14%)”View highlighted excerpt for this quote
Seronegative“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (7%)”View highlighted excerpt for this quote
Baseline QMG, mean (SD)“14·3 (3·5)”View highlighted excerpt for this quote“17·3 (1·5)”View highlighted excerpt for this quote“15·9 (4·5)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote“15·3 (4·1)”View highlighted excerpt for this quote
Baseline MG-ADL, mean (SD)“8·7 (3·8)”View highlighted excerpt for this quote“10·7 (3·5)”View highlighted excerpt for this quote“10·7 (3)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote“10 (3·2)”View highlighted excerpt for this quote
Baseline MGC, mean (SD)“19·3 (6·7)”View highlighted excerpt for this quote“24·7 (4·7)”View highlighted excerpt for this quote“23 (5·2)”View highlighted excerpt for this quote“13”View highlighted excerpt for this quote“21·9 (5·7)”View highlighted excerpt for this quote
Baseline MG-QoL-15r, mean (SD)“23·3 (3·1)”View highlighted excerpt for this quote“19·1 (9)”View highlighted excerpt for this quote“19·7 (5·1)”View highlighted excerpt for this quote“12”View highlighted excerpt for this quote“19·9 (5·8)”View highlighted excerpt for this quote
Prior eculizumab“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (14%)”View highlighted excerpt for this quote
Prior rituximab“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (14%)”View highlighted excerpt for this quote
Prior IVIg“1/3”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“7/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote“12 (86%)”View highlighted excerpt for this quote
Prior plasma exchange“0”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“5/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (36%)”View highlighted excerpt for this quote
Prior thymectomy“1/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (43%)”View highlighted excerpt for this quote
Prior MG crisis requiring intubation“1/3”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (29%)”View highlighted excerpt for this quote
Pyridostigmine at baseline“2/3”View highlighted excerpt for this quote“3/3”View highlighted excerpt for this quote“6/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“11 (79%)”View highlighted excerpt for this quote
Prednisone at baseline“3/3”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“5/7”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“10 (71%)”View highlighted excerpt for this quote
Efficacy results
Measures of disease severity at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
Measure at Week 12All, n=9 (mean change, 95% CI)Arm 1, n=2 (individual values)Arm 2, n=7 (mean change, 95% CI)AChR+, n=6 (mean change, 95% CI)MuSK+, n=2 (individual values)Seronegative, n=1
MG-ADL“−5·9 [−9, −2·8]”View highlighted excerpt for this quote“−6, −8”View highlighted excerpt for this quote“−6 [−15, +3]”View highlighted excerpt for this quote“−6 [−11, −1]”View highlighted excerpt for this quote“−3, −4”View highlighted excerpt for this quote“−8”View highlighted excerpt for this quote
QMG“−7 [−11, −3]”View highlighted excerpt for this quote“−5, −3”View highlighted excerpt for this quote“−8 [−20, +4]”View highlighted excerpt for this quote“−5 [−10, 0]”View highlighted excerpt for this quote“−9, −5”View highlighted excerpt for this quote“−17”View highlighted excerpt for this quote
MGC“−14 [−19, −9]”View highlighted excerpt for this quote“−7, −11”View highlighted excerpt for this quote“−15 [−29, −1]”View highlighted excerpt for this quote“−14 [−21, −7]”View highlighted excerpt for this quote“−14, −7”View highlighted excerpt for this quote“−22”View highlighted excerpt for this quote
MG-ADL decrease ≥2, No.“8/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“6/7”View highlighted excerpt for this quote“5/6”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
MGC decrease ≥3, No.“9/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“7/7”View highlighted excerpt for this quote“6/6”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
QMG decrease ≥3, No.“8/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“6/7”View highlighted excerpt for this quote“5/6”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
MG-ADL decrease ≥6, No. (post hoc)“5/9”View highlighted excerpt for this quote“2/2”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“4/6”View highlighted excerpt for this quote“0/2”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
Company-reported retreatment analysis: baseline characteristics of the pooled case series, 5 participants
CharacteristicParticipants (n=5)
Age, mean (SD)“58 (12) years”
Age range“49–79”
Women, n (%)“4 (80%)”
AChR+ gMG, n (%)“4 (80%)”
MG-ADL at baseline before initial treatment, mean (SD)“9.2 (3.1)”
MG-ADL at baseline before retreatment, mean (SD)“9.6 (3.4)”
Median interval between end of initial treatment course and first retreatment infusion“16.6 months”; “(range 11.7–22.6)”
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
Safety results
Serious adverse events: influenza before treatment, grade 3 urticaria, and myocardial infarction
Adverse events related to Descartes-08 by part and arm: all 14 participants
TermGradePart 1 (n=3)Part 2, all arms (n=11)Part 2 Arm 1 (n=3)Part 2 Arm 2 (n=7)Part 2 Arm 3 (n=1)
Hand numbness“2”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quoteNot reportedNot reportedNot reportedNot reported
Headache“1”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“5 (45%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
Muscle soreness“1”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Nausea“1”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“4 (36%)”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“2/7”View highlighted excerpt for this quoteNot reported
Rash“3”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quoteNot reportedNot reported
Itchy throat“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quote“1/1”View highlighted excerpt for this quote
Vomiting“1”View highlighted excerpt for this quoteNot reported“3 (27%)”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Weakness“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quote“2/3”View highlighted excerpt for this quoteNot reportedNot reported
Line infiltration“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quoteNot reportedNot reported
Fever“1”View highlighted excerpt for this quoteNot reported“4 (36%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“3/7”View highlighted excerpt for this quoteNot reported
Shortness of breath“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Chills“1”View highlighted excerpt for this quoteNot reported“2 (18%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Diarrhea“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quote“1/3”View highlighted excerpt for this quote“1/7”View highlighted excerpt for this quoteNot reported
Gum inflammation“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Teeth sensitivity“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Night sweats“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Restless leg“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Lightheadedness“1”View highlighted excerpt for this quoteNot reported“1 (9%)”View highlighted excerpt for this quoteNot reported“1/7”View highlighted excerpt for this quoteNot reported
Company-reported retreatment analysis: safety events after initial treatment and retreatment, 5 participants
Safety eventInitial treatment (n=5)Retreatment (n=5)
Serious adverse events“1”“0”
Infusion-related reaction“16/30 infusions”“17/30 infusions”
Infusion-related reaction, grade 1“10”“12”
Infusion-related reaction, grade 2“6”“5”
Tachycardia“1”“5”
CRS“0”“0”
ICANS“0”“0”
Cytopenias“0”“0”
Hypogammaglobulinemia“0”“0”
Study limitations
Summary
  • Design: the study was open label, nonrandomized, and without a control arm, and the authors state that a placebo effect cannot be excluded and that comparison with historical controls is not conclusive. Part 2 participants were assigned to dosing arms at the investigator's discretion, taking participant preference into account.
  • Sample size: 14 participants were enrolled (3 in Part 1 and 11 in Part 2), and no formal power analysis was performed. The week 12 efficacy analysis included 9 Part 2 participants, and only 2 participants had MuSK antibody-positive disease and 1 had seronegative disease. Three participants had MGFA class II disease, which the authors note may improve to minimum symptom expression with conventional treatment.
  • Endpoints: efficacy measures were secondary endpoints with no prespecified primary efficacy time point, and the analysis of MG-ADL decreases of 6 points or more was post hoc. Corticosteroid tapering was permitted after week 4 at the investigator's discretion, and the authors state that an effect of the unchanged maintenance dose cannot be excluded in the absence of a control arm.
  • Follow-up and attrition: median follow-up in Part 2 was 5 months (range 3 to 9) in the initial report. By week 16 all twice-weekly arm participants were off study (adverse event, n = 1; worsening symptoms, n = 2), and the single monthly-arm participant withdrew after 3 of 6 infusions. The 12-month analysis is limited to the 7 weekly-arm participants, of whom 5 maintained clinically meaningful improvement at month 12.
  • Retreatment and biomarkers: the authors state that more experience with initial treatment and retreatment is needed, that allergic reactions including anaphylaxis cannot be excluded, and that circulating antibody titers may not reflect tissue concentrations. The pooled retreatment case series of 5 participants is company-reported.
  • Reporting: the sponsor took part in the design, data collection, interpretation, analysis, manuscript writing, and decision to submit. The text gives the most common treatment-related adverse events in Part 2 as 5 (45%), 4 (36%), and 4 (36%) “of 14 patients”, while the table reports these counts for Part 2 (n = 11). The month-12 MG-QoL-15r change is printed as “−7.7 [−15.6 to −8.4]”, an interval that does not contain its point estimate.
Small, open-label, uncontrolled design: author-stated limitations